Arthur E Frankel
Scott and White Cancer Research
Institute, Temple, TX, USA
Clinical Pharmacology: Advances and Applications is now in its second year. The turnaround time for the publishing of manuscripts is a few weeks. Peer reviews are high quality, and the journal is open access, filling an important niche in academic medical publishing.
Specifically, the journal was designed to bridge the gap between basic science and clinical practice. Because of the explosion in the market of new drugs and biomarkers secondary to in silico drug design, high-throughput screens, large cooperative group clinical trials, and patient characterizations by genomic and proteomic analyses, we now have a huge amount of information on drug targets and host responses. Although such a plethora of knowledge should promise rapid advances, in fact in many cases it has led to a partial paralysis of action both by pharmacologists and by physicians. How do we make sense of this massive complexity? Will any action we take be seen as erroneous in weeks or months?
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]